Literature DB >> 18094121

Strand-specific 5'-O-methylation of siRNA duplexes controls guide strand selection and targeting specificity.

Po Yu Chen1, Lasse Weinmann, Dimos Gaidatzis, Yi Pei, Mihaela Zavolan, Thomas Tuschl, Gunter Meister.   

Abstract

Small interfering RNAs (siRNAs) and microRNAs (miRNAs) guide catalytic sequence-specific cleavage of fully or nearly fully complementary target mRNAs or control translation and/or stability of many mRNAs that share 6-8 nucleotides (nt) of complementarity to the siRNA and miRNA 5' end. siRNA- and miRNA-containing ribonucleoprotein silencing complexes are assembled from double-stranded 21- to 23-nt RNase III processing intermediates that carry 5' phosphates and 2-nt overhangs with free 3' hydroxyl groups. Despite the structural symmetry of a duplex siRNA, the nucleotide sequence asymmetry can generate a bias for preferred loading of one of the two duplex-forming strands into the RNA-induced silencing complex (RISC). Here we show that the 5'-phosphorylation status of the siRNA strands also acts as an important determinant for strand selection. 5'-O-methylated siRNA duplexes refractory to 5' phosphorylation were examined for their biases in siRNA strand selection. Asymmetric, single methylation of siRNA duplexes reduced the occupancy of the silencing complex by the methylated strand with concomitant elimination of its off-targeting signature and enhanced off-targeting signature of the phosphorylated strand. Methylation of both siRNA strands reduced but did not completely abolish RNA silencing, without affecting strand selection relative to that of the unmodified siRNA. We conclude that asymmetric 5' modification of siRNA duplexes can be useful for controlling targeting specificity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18094121      PMCID: PMC2212253          DOI: 10.1261/rna.789808

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  81 in total

Review 1.  The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis.

Authors:  Michelle A Carmell; Zhenyu Xuan; Michael Q Zhang; Gregory J Hannon
Journal:  Genes Dev       Date:  2002-11-01       Impact factor: 11.361

2.  Expression profiling reveals off-target gene regulation by RNAi.

Authors:  Aimee L Jackson; Steven R Bartz; Janell Schelter; Sumire V Kobayashi; Julja Burchard; Mao Mao; Bin Li; Guy Cavet; Peter S Linsley
Journal:  Nat Biotechnol       Date:  2003-05-18       Impact factor: 54.908

Review 3.  Argonaute and RNA--getting into the groove.

Authors:  Ji-Joon Song; Leemor Joshua-Tor
Journal:  Curr Opin Struct Biol       Date:  2006-01-24       Impact factor: 6.809

4.  Cleavage of the siRNA passenger strand during RISC assembly in human cells.

Authors:  Philipp J F Leuschner; Stefan L Ameres; Stephanie Kueng; Javier Martinez
Journal:  EMBO Rep       Date:  2006-01-20       Impact factor: 8.807

5.  3' UTR seed matches, but not overall identity, are associated with RNAi off-targets.

Authors:  Amanda Birmingham; Emily M Anderson; Angela Reynolds; Diane Ilsley-Tyree; Devin Leake; Yuriy Fedorov; Scott Baskerville; Elena Maksimova; Kathryn Robinson; Jon Karpilow; William S Marshall; Anastasia Khvorova
Journal:  Nat Methods       Date:  2006-03       Impact factor: 28.547

6.  Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways.

Authors:  Luis Alfonso Martinez; Irina Naguibneva; Heike Lehrmann; Arlette Vervisch; Thierry Tchénio; Guillermina Lozano; Annick Harel-Bellan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-28       Impact factor: 11.205

7.  Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation.

Authors:  Tim A Rand; Sean Petersen; Fenghe Du; Xiaodong Wang
Journal:  Cell       Date:  2005-11-03       Impact factor: 41.582

8.  Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes.

Authors:  Christian Matranga; Yukihide Tomari; Chanseok Shin; David P Bartel; Phillip D Zamore
Journal:  Cell       Date:  2005-11-03       Impact factor: 41.582

9.  TRBP, a regulator of cellular PKR and HIV-1 virus expression, interacts with Dicer and functions in RNA silencing.

Authors:  Astrid D Haase; Lukasz Jaskiewicz; Haidi Zhang; Sébastien Lainé; Ragna Sack; Anne Gatignol; Witold Filipowicz
Journal:  EMBO Rep       Date:  2005-10       Impact factor: 8.807

10.  The role of PACT in the RNA silencing pathway.

Authors:  Yoontae Lee; Inha Hur; Seong-Yeon Park; Young-Kook Kim; Mi Ra Suh; V Narry Kim
Journal:  EMBO J       Date:  2006-01-19       Impact factor: 11.598

View more
  64 in total

Review 1.  Action and reaction: the biological response to siRNA and its delivery vehicles.

Authors:  Rosemary L Kanasty; Kathryn A Whitehead; Arturo J Vegas; Daniel G Anderson
Journal:  Mol Ther       Date:  2012-01-17       Impact factor: 11.454

Review 2.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

3.  Short RNA duplexes guide sequence-dependent cleavage by human Dicer.

Authors:  Lucien Bergeron; Jean-Pierre Perreault; Sherif Abou Elela
Journal:  RNA       Date:  2010-10-25       Impact factor: 4.942

4.  Quantitative evaluation of siRNA delivery in vivo.

Authors:  Yi Pei; Paula J Hancock; Hangchun Zhang; René Bartz; Craig Cherrin; Nathalie Innocent; Colin J Pomerantz; Jessica Seitzer; Martin L Koser; Marc T Abrams; Yan Xu; Nelly A Kuklin; Paul A Burke; Alan B Sachs; Laura Sepp-Lorenzino; Stanley F Barnett
Journal:  RNA       Date:  2010-10-12       Impact factor: 4.942

Review 5.  Designing highly active siRNAs for therapeutic applications.

Authors:  S Patrick Walton; Ming Wu; Joseph A Gredell; Christina Chan
Journal:  FEBS J       Date:  2010-12       Impact factor: 5.542

Review 6.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 7.  Preclinical and clinical development of siRNA-based therapeutics.

Authors:  Gulnihal Ozcan; Bulent Ozpolat; Robert L Coleman; Anil K Sood; Gabriel Lopez-Berestein
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

8.  Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects.

Authors:  Chan Il Chang; Jae Wook Yoo; Sun Woo Hong; Shi Eun Lee; Hye Suk Kang; Xiangao Sun; Harry A Rogoff; Changill Ban; Soyoun Kim; Chiang J Li; Dong-Ki Lee
Journal:  Mol Ther       Date:  2009-01-20       Impact factor: 11.454

9.  Argonaute-bound small RNAs from promoter-proximal RNA polymerase II.

Authors:  Jesse R Zamudio; Timothy J Kelly; Phillip A Sharp
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

Review 10.  RNA interference-based therapeutics for human immunodeficiency virus HIV-1 treatment: synthetic siRNA or vector-based shRNA?

Authors:  Sandesh Subramanya; Sang-Soo Kim; N Manjunath; Premlata Shankar
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.